GLP-1 receptor agonist use and weight change in patients with breast cancer Journal Article
| Authors: | Shen, S.; Liu, B.; Fanti, C.; Bromberg, M.; Chen, Y.; Chang, C.; Iyengar, N. M. |
| Article Title: | GLP-1 receptor agonist use and weight change in patients with breast cancer |
| Abstract: | Obesity and weight gain are associated with adverse outcomes following breast cancer diagnosis; some breast cancer treatments contribute to postdiagnosis weight gain. We evaluated patients with breast cancer who were prescribed a glucagon-like peptide-1 receptor agonist (GLP-1 RA), with follow-up weight data available. Weights were categorized by time from GLP-1 RA initiation; a linear mixed effects model with a random intercept for baseline weight was used to assess mean weight change at each time point. Among 75 patients, the median age was 52 years (range, 27-74), 62 (86%) were postmenopausal, and 59 (79%) had diabetes. Additionally, 68 (91%) patients had stage 0 to III breast cancer, and 62 (84%) had estrogen receptor-positive disease. The median body mass index (BMI) at baseline was 34 (range, 23-50). The mean weight change was-2.9 kg (95% CI, -4.1 to-1.7) at 6 months and-4.2 kg (95% CI, -5.5 to-2.9) at 12 months; mean weight change at 12 months was-5% (95% CI, -6%to-3%). In univariable and multivariable analyses, age, baseline BMI, diabetes, stage, histology, receptor status, menopausal status, and concurrent endocrine therapy use were not significantly associated with 5% or greater weight loss at 12 months. These results support the development of clinical trials to optimize the use and dosing of GLP-1 RAs for weight loss in patients with breast cancer. |
| Journal Title: | Oncology (Norwalk) |
| Volume: | 39 |
| Issue: | 7 |
| ISSN: | 0890-9091 |
| Publisher: | C M P Medica LLC * The Oncology Group |
| Date Published: | 2025-08-01 |
| Start Page: | 294 |
| End Page: | 296 |
| Language: | English |
| ACCESSION: | WOS:001555905200005 |
| PROVIDER: | wos |
| PUBMED: | 40834286 |
| DOI: | 10.46883/2025.25921046 |
| Notes: | Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work